Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
GlaxoSmithKline ( (GB:GSK) ) has shared an update.
GSK has disclosed that, as of 31 December 2025, its issued share capital comprised 4,315,445,026 ordinary shares of 31¼ pence each, of which 240,019,489 are held in treasury. This leaves a total of 4,075,425,537 voting rights in the company, a key reference figure for investors monitoring or reporting changes in their shareholdings under UK financial transparency rules, and underscores GSK’s compliance with ongoing market disclosure obligations.
The most recent analyst rating on (GB:GSK) stock is a Hold with a £17.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
Spark’s Take on GB:GSK Stock
According to Spark, TipRanks’ AI Analyst, GB:GSK is a Outperform.
GlaxoSmithKline’s overall stock score is driven by strong financial performance and favorable valuation metrics. The company’s strategic initiatives, including share buybacks and R&D investments, support its growth outlook. However, challenges in cash flow and certain market segments warrant cautious optimism.
To see Spark’s full report on GB:GSK stock, click here.
More about GlaxoSmithKline
GSK is a global biopharmaceutical company focused on uniting science, technology and talent to develop innovative medicines and vaccines to get ahead of disease, with operations headquartered in London and a strong presence in major healthcare markets worldwide.
Average Trading Volume: 8,286,325
Technical Sentiment Signal: Buy
Current Market Cap: £73.89B
For detailed information about GSK stock, go to TipRanks’ Stock Analysis page.